Cohance Lifesciences Limited (BOM:543064)
India flag India · Delayed Price · Currency is INR
425.05
-0.65 (-0.15%)
At close: Jul 31, 2026

Cohance Lifesciences Cash Flow Statement

Millions INR. Fiscal year is Apr - Mar.

Operating Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Net Income
1,7924,8733,0034,1134,538
Depreciation & Amortization
1,8731,668546464.6390.22
Other Amortization
----3.91
Loss (Gain) From Sale of Assets
-16.20.20.70.07-0.01
Loss (Gain) From Sale of Investments
-12.2-235.2-449.1-156.87-82.03
Stock-Based Compensation
-38.1216.219.7--
Provision & Write-off of Bad Debts
10.7----
Other Operating Activities
-134.2218.28.593.58389.52
Change in Accounts Receivable
1,025-1,336128.21,245-1,361
Change in Inventory
-945.81,408816.1-293.93-823.37
Change in Accounts Payable
128.4-78.8-225.2-357.99232.04
Change in Other Net Operating Assets
----535.0512.55
Operating Cash Flow
3,6836,7343,8484,5723,300
Operating Cash Flow Growth
-45.30%75.00%-15.84%38.54%-13.74%

Investing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Capital Expenditures
-2,199-3,168-518.8-2,859-751.87
Sale of Property, Plant & Equipment
205.21.4-0.720.01
Cash Acquisitions
--7,280---
Investment in Securities
-568.86,231-3,101844.55-560.72
Other Investing Activities
16.7318.2-4.263.79-48.8
Investing Cash Flow
-2,546-3,897-3,624-1,950-1,361

Financing Activities

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Long-Term Debt Issued
-373.1---
Total Debt Issued
-373.1---
Short-Term Debt Repaid
-12.1-3,120-270.4-26.11-385.66
Long-Term Debt Repaid
-1,123-251.1-60-241.33-98.58
Total Debt Repaid
-1,135-3,371-330.4-267.43-484.24
Net Debt Issued (Repaid)
-1,135-2,998-330.4-267.43-484.24
Issuance of Common Stock
324.388---
Common Dividends Paid
----2,037-1,018
Other Financing Activities
-841.1-363.7-69.5-115.56-62.31
Financing Cash Flow
-1,652-3,274-399.9-2,420-1,565

Net Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Foreign Exchange Rate Adjustments
38.920.8--0
Net Cash Flow
-475.1-416.7-175.7202.39373.82

Free Cash Flow

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Free Cash Flow
1,4843,5663,3291,7132,548
Free Cash Flow Growth
-58.37%7.11%94.35%-32.78%-6.21%
Free Cash Flow Margin
6.54%13.67%31.66%12.78%19.30%
Free Cash Flow Per Share
3.889.2813.086.7310.01
Levered Free Cash Flow
485.73-3,6062,9671,0791,027
Unlevered Free Cash Flow
718.48-3,3493,0141,1591,066

Additional Metrics

Fiscal Year
FY 2026FY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Mar '25 Mar '24 Mar '23 Mar '22
Cash Interest Paid
341.1363.769.5115.5662.31
Cash Income Tax Paid
677.71,7591,1001,4581,843
Change in Working Capital
207.6-7.3719.157.68-1,940